Lesinurad/allopurinol achieves clinically relevant and statistically significant reductions in serum urate (sUA) in patients with inadequate response to allopurinol alone, according to a study of 227 such patients who were randomized to receive 200, 400, or 600 mg/day of lesinurad or matching placebo along with their prestudy allopurinol dose. Researchers found:

• Lesinurad 200, 400, 600 mg combined with allopurinol produced significant mean percent reductions from baseline sUA of 16%, 22%, and 30%, respectively vs a mean 3% increase with placebo.

• Similar results were seen in patients with mild or moderate renal insufficiency.

• Incidence of ≥ 1 treatment-emergent adverse event was 46%, 48%, and 54% with lesinurad 200, 400, 600 mg, respectively vs 46% with placebo, with no deaths or serious adverse events.

• Most frequent treatment-emergent adverse events were gout flares, arthralgia, headache, and nasopharyngitis.

Citation: Perez-Ruiz F, Sundy JS, Miner JN, Cravets M, Storgard C. Lesinurad in combination with allopurinol: results of a phase 2, randomised, double-blind study in patients with gout with an inadequate response to allopurinol. [Published online ahead of print January 7, 2016]. Ann Rheum Dis. doi: 10.1136/annrheumdis-2015-207919.